Systemic lupus erythematosus (SLE) is a chronic multisystem inflammatory autoimmune disease
that is characterized by a number of immunological abnormalities. Disease onset is triggered by
ill‑defined environmental factors in genetically susceptible individuals. C1q plays a key role in
apoptotic cell and immune complex removal, and hence it is a very important functional molecule
in SLE pathogenesis. Investigation of the relationship between peripheral lymphocyte apoptosis
and serum levels of anti‑C1q autoantibodies in SLE patients suggests that increased serum
levels of anti‑C1q autoantibodies are responsible for apoptosis and may play a pathogenic
role in SLE patients, especially in active disease.
Objectives
The aim of this study was to measure the serum level of anti‑C1q in SLE patients, and to
evaluate the correlation between anti‑C1q and SLE disease activity, especially renal activity.
Patients and methods
Fifty SLE patients diagnosed according to the Systemic Lupus International Collaborating Clinics
classification criteria 2012 and 33 healthy volunteers who were age and sex matched were
included in the study. SLE activity was assessed using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI), and renal activity was assessed using the renal SLEDAI.
Anti‑C1q was estimated using enzyme‑linked immunosorbent assay kit.
Results
Serum anti‑C1q was significantly higher in SLE patients (64.86 ± 27.88 U/ml) compared with
healthy controls (30.15 ± 13.93 U/ml) (P < 0.000). There was a significantly positive correlation
between anti‑C1q and the SLEDAI (P = 0.035, r = 0.299) and the renal SLEDAI (P = 0.025,
r = 0.316). Anti‑C1q has a sensitivity and specificity of 92.7 and 66.7%, respectively, a positive
predictive value of 92.7%, negative predictive value of 66.7%, and 88.0% accuracy for detecting
SLE disease activity, whereas for lupus nephritis diagnosis anti‑C1q has a sensitivity and
specificity of 94.12 and 50.0%, respectively, a positive predictive value of 80.0%, negative
predictive value of 80.0%, and 80.0% accuracy.
Conclusion
Our results support the finding that anti‑C1q level might be used as a marker for SLE activity
and not lupus nephritis in adult SLE patients.